Duke logo

PLANET - Clinical Trial

What is the Purpose of this Study?

We are doing this study to learn if the study drug combination of pembrolizumab and lanreotide is safe for patients and also if these drugs can slow, stop, or make your tumor smaller.

What is the Condition Being Studied?

Neuroendocrine tumor of the gastrointestinal (GI) tract or pancreas (GEP-NET)

Who Can Participate in the Study?

Adults who:
- Have gastroenteropancreatic neuroendocrine tumor (GEP-NETs)
- Do not have an active infection requiring systemic therapy

Age Group
Adults

What is Involved?

If you choose to join this study, you will:
- Get Pembrolizumab by injection into your vein every 3 weeks and Lanreotide by injection under your skin every 3 weeks
-- These 21-day cycles will be repeated until your cancer gets worse or you are no longer able to tolerate the study drugs

Study Details

Full Title
Phase Ib/II Study of Pembrolizumab with Lanreotide Depot for Gastroenteropancreatic Neuroendocrine Tumors
Principal Investigator
Protocol Number
IRB:PRO00074917
NCT:NCT03043664
Phase
Phase I/II
ClinicalTrials.gov
Contact the Duke Recruitment Innovation Center
MyResearchPartners@duke.edu
or
919-681-5698